Low-Dose Eribulin Promotes NK Cell-Mediated Therapeutic Efficacy in Bladder Cancer
These findings are paradigm-shifting given that chemotherapy is traditionally considered immunosuppressive. Our study reveals the novel effect of low-dose eribulin chemotherapy in inhibiting bladder tumor growth by enhancing anti-tumor NK cell immunity, challenging previous assumptions and opening new therapeutic approaches to improve antitumor immunity.
Authors
- M. Kim
- Robert S. Svatek (ORCID: https://orcid.org/0000-0002-0239-1338)
- Neelam Mukherjee (ORCID: https://orcid.org/0000-0003-1974-6075)
- April L. Risinger (ORCID: https://orcid.org/0000-0002-4363-3268)
- Niannian Ji (ORCID: https://orcid.org/0000-0001-5852-6484)
- Zaineb Hassouneh (ORCID: https://orcid.org/0000-0002-2919-7164)
- Onika Noel
- Jordan Svatek
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- Mays Cancer Center at UT Health San Antonio (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-11-19
- DOI
- https://doi.org/10.3390/cancers16223875
- Citations
- 1
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.24
Funders
- Max and Minnie Tomerlin Voelcker Fund